Hyperbaric oxygen therapy addresses the neurobiological mechanisms driving Alzheimer's disease
Hyperbaric oxygen therapy addresses the neurobiological mechanisms driving Alzheimer's disease
Understanding Alzheimer's disease and how HBOT addresses its neurobiological drivers
Alzheimer's disease is the most common cause of dementia, accounting for 60 to 80% of cases. It is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta plaques and neurofibrillary tau tangles in the brain, leading to synaptic dysfunction, neuroinflammation and progressive neuron loss. Alzheimer's affects approximately 6.7 million Americans, with prevalence expected to more than double by 2060.
The cognitive decline of Alzheimer's follows a characteristic pattern: early memory impairment — particularly difficulty forming new memories — progressing to language difficulties, disorientation, impaired judgment and eventual loss of the ability to manage daily activities. Current approved medications (acetylcholinesterase inhibitors and memantine) modestly improve symptoms but do not slow the underlying neurodegeneration. Newer anti-amyloid antibodies represent a more disease-modifying approach but carry significant risks and demonstrate modest benefit at best in controlled trials.
The neurobiological landscape of Alzheimer's has revealed three mechanisms that HBOT is well-positioned to address: cerebral hypoperfusion (reduced blood flow in temporal and parietal cortices that precedes and accompanies cognitive decline), neuroinflammation (chronic microglial activation driven by amyloid accumulation that accelerates neuron loss), and mitochondrial dysfunction (impaired neuronal energy metabolism that compromises cell survival). HBOT directly targets all three. While HBOT is not a cure for Alzheimer's, growing clinical evidence suggests it can meaningfully improve cognitive function and quality of life, particularly when initiated in earlier stages when more viable neurons remain.
Progressive memory loss, particularly difficulty forming new memories
Language difficulties — word-finding problems, repetition, reduced vocabulary
Disorientation to time, place and person in moderate-to-advanced stages
Impaired judgment and executive function affecting daily decision-making
Behavioral changes — agitation, depression, anxiety, sleep disturbance
Progressive loss of independence in activities of daily living
How HBOT addresses the biological drivers of Alzheimer's disease
Alzheimer's disease involves multiple overlapping pathological processes. HBOT targets the neurobiological mechanisms that are most amenable to oxygen-mediated intervention: hypoperfusion, neuroinflammation and mitochondrial dysfunction.
Restores cerebral blood flow in Alzheimer's-affected brain regions
Reduces neuroinflammation driving amyloid pathology
Enhances amyloid clearance mechanisms
Improves memory, attention and cognitive processing speed
Activates neurotrophic factors that support neuron survival
Promotes mitochondrial function and cellular energy production
For Providers
Research on HBOT in Alzheimer's disease
Research on HBOT specifically for Alzheimer's disease is in an active and promising phase, anchored by strong mechanistic evidence and supported by clinical case series and closely related cognitive aging RCT data.
Efrati et al. — cognitive aging RCT (2020): A landmark randomized controlled trial published in Aging by Shai Efrati and colleagues at the Sagol Center enrolled 35 healthy adults over 64 and randomized them to 60 sessions of HBOT at 2.0 ATA or no intervention. The HBOT group demonstrated significant improvements in memory, attention, information processing speed and executive function on objective neuropsychological testing, with MRI cerebral blood flow analysis confirming significantly increased perfusion in multiple brain regions including the hippocampus, the memory structure most vulnerable in Alzheimer's disease. Strikingly, the study also documented telomere lengthening and reduced senescent cell burden in peripheral blood cells — objective biological markers of cellular rejuvenation. [Hachmo Y et al. Aging (Albany NY). 2020;12(22):22445–61. PMID: 33207385]
Cerebral hypoperfusion in Alzheimer's: Reduced cerebral blood flow — particularly in the entorhinal cortex, hippocampus, posterior cingulate cortex and temporal-parietal association areas — is one of the earliest and most consistent neuroimaging findings in Alzheimer's disease, preceding cognitive symptoms by years. This hypoperfusion pattern is directly addressed by HBOT's mechanism of increasing cerebral oxygen delivery. [Jagust WJ et al. Neurology. 1997;48(5):1404–1409. PMID: 9153480]
Neuroinflammation as a therapeutic target: Neuroinflammation — characterized by microglial hyperactivation, astrocyte reactivity and elevated TNF-α and IL-1β — is now recognized as a central amplifier of Alzheimer's neurodegeneration rather than merely a secondary response. HBOT's well-documented anti-inflammatory effects target this pathway directly. [Heneka MT et al. Lancet Neurol. 2015;14(4):388–405. PMID: 25792098]
Amyloid clearance and glymphatic function: Emerging preclinical evidence suggests HBOT may enhance glymphatic clearance of amyloid-beta, the protein that aggregates into the plaques characteristic of Alzheimer's. The glymphatic system operates primarily during sleep and depends on adequate cerebral oxygenation and vascular tone for efficient waste clearance. HBOT's effects on cerebral oxygenation and vascular function may support glymphatic pathway function, though this mechanism requires further clinical validation.
Important caveat: A specific, powered randomized controlled trial of HBOT in diagnosed Alzheimer's disease patients has not yet been published. The evidence base is built on the mechanistic rationale, the cognitive aging RCT, and case series. We present this evidence honestly and encourage patients and families to discuss HBOT with their neurologist.
Our Alzheimer's HBOT protocol at Bay Area Hyperbarics
HBOT for Alzheimer's is an adjunct to current medical management, not a replacement for it. The earlier it is initiated in the disease course, the more viable neurons remain to benefit from improved oxygenation and neuroprotective signaling. We encourage discussion with the treating neurologist before beginning treatment.
Neurological assessment and care team coordination
Our medical team reviews the patient's Alzheimer's stage, current cognitive status, medications and treatment goals. We coordinate with the treating neurologist to ensure HBOT is integrated as an adjunct to current Alzheimer's care — including any approved medications — not a replacement for medical management. We discuss realistic expectations with both patients and families at the initial consultation.
40-session HBOT course to improve brain oxygenation and reduce neuroinflammation
Patients breathe 100% oxygen at 1.5 to 2.0 atmospheres absolute for 60 to 90 minutes per session. Alzheimer's protocols typically involve 40 to 60 sessions as an initial course, with cognitive reassessment at completion. The Efrati protocol for cognitive aging used 60 sessions at 2.0 ATA in published trials, and we use this as a guiding framework.
Cognitive outcome monitoring and maintenance planning
We track cognitive function, memory, orientation, quality of life and caregiver-reported functional status throughout treatment. For patients who respond well, maintenance HBOT courses — typically every 3 to 6 months — help sustain the improvements achieved and may slow the rate of cognitive decline over time.
Frequently Asked Questions
Answers to the questions Alzheimer's patients and families most often ask about hyperbaric oxygen therapy.
No. There is currently no cure for Alzheimer's disease, and no intervention — including HBOT — reverses established neurodegeneration. HBOT works by improving the brain's metabolic environment through improved oxygenation and reduced neuroinflammation, potentially slowing the rate of progression and improving cognitive function in areas of viable but metabolically impaired tissue. The best candidates for meaningful benefit are patients in earlier stages of disease where more neurons remain viable. We discuss realistic expectations openly at your consultation.
Seeking options for Alzheimer's disease? Ask us about HBOT
Bay Area Hyperbarics offers HBOT as a supportive adjunctive therapy for Alzheimer's disease patients and their families. Call us to schedule a consultation and discuss whether HBOT is appropriate for your loved one's stage of disease.
